We have started on a Brave New Path
Brain Cancer and Dementia are two of the biggest challenges of the 21st century.
We believe we have a Solution and we need your Investment to win the fight
Hal.o NIR Non-Ionizing Radiotherapy is a medical device
designed to address treatment access to the brain.
Now in the second phase of product development, the Hal.o NIR (Non-Ionizing Radiotherapy) uses MR guidance, to non-invasively reach solid tumors of the brain and potentially challenge the amyloid plaque build-up found in patients with Alzheimer's and associated dementia. NIR is a non-surgical, non-pharmaceutical, non-invasive treatment using a form of cell penetrating radiotherapy that can reach the center of the brain.
Numerical modeling demonstrates the systems ability to focus and steer a 2.1cm x 1.2 cm ellipsoidal focal pattern at any depth of the brain. Applied to solid tumors, the system increases the radiosensitivity of the tumor. By focusing on the hippocampus, we believe we can reverse atrophy and restart the production of healthy neurons in order to delay or prevent brain degradation associated with Alzheimer's and dementia diseases.
1 in 10 people age 65 and older has Alzheimer's dementia
Every 65 seconds someone new is diagnosed with this disease, becoming the sixth leading cause of death in this country
Drugs have Failed
99% of all drug trials have failed. Out of 400 clinical trials, between 2002 and 2012, only one drug (memantine) was approved. And the few drugs on the market, not one can not stop the progression of the disease, only manage the symptoms. Most recently the top pharmaceutical companies (Eli Lilly, Johnson & Johnson, Merck, Pfizer and Roche) have all failed large phase 3 trials in their attempt to treat Alzheimer's. According to an article published in the Annals of the New York Academy of Sciences, the total costs of an AD drug development program is estimated at $5.6 billion, and the process takes 13 years from preclinical studies to approval.
